Aspira Women's Health Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Aspira Women's Health Inc. (AWHL) filed its Q1 2024 10-Q report, detailing financial activities and agreements.</b>

AI Summary

Aspira Women's Health Inc. (AWHL) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Aspira Women's Health Inc. filed a 10-Q report for the period ending March 31, 2024. The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems. Key dates mentioned include March 31, 2024, for the reporting period and May 15, 2024, as the filing date. The filing references various agreements including a Purchase Agreement with Lincoln Park Capital Fund, an Equity Line of Credit Agreement, and lease agreements for its Austin, Texas facility. The company is involved in the In Vitro & In Vivo Diagnostic Substances industry.

Why It Matters

For investors and stakeholders tracking Aspira Women's Health Inc., this filing contains several important signals. The 10-Q filing provides a detailed look into the company's financial health and operational status as of March 31, 2024, which is crucial for investors to assess performance and future prospects. The report highlights ongoing agreements and financing activities, such as the Lincoln Park Capital Fund Purchase Agreement and Equity Line of Credit, indicating potential capital raises and operational support.

Risk Assessment

Risk Level: — Aspira Women's Health Inc. shows moderate risk based on this filing. The company's financial disclosures in this 10-Q are critical, but without specific revenue, net income, or debt figures provided in the input, a definitive risk assessment is challenging. However, the mention of various agreements and past company name changes suggests a history of restructuring or financing activities that could imply inherent financial risks.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the full 10-Q filing to understand Aspira Women's Health's current financial position and future outlook.

Key Numbers

• 2024-03-31 — Reporting Period End Date (Conformed Period of Report)
• 2024-05-15 — Filing Date (Filed As Of Date)
• 2835 — SIC Code (Standard Industrial Classification)
• 330595156 — IRS Number (Company Tax ID)
• DE — State of Incorporation (Company Legal Structure)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Filer
• AWHL (company) — Ticker Symbol
• 20240331 (date) — Conformed Period of Report
• 20240515 (date) — Filed As Of Date
• Vermillion, Inc. (company) — Former Company Name
• Ciphergen Biosystems Inc (company) — Former Company Name
• Abiotic Systems (company) — Former Company Name
• Lincoln Park Capital Fund (company) — Party to Purchase Agreement

FAQ

Industry Context

Aspira Women's Health Inc. operates in the In Vitro & In Vivo Diagnostic Substances industry, focusing on diagnostic solutions.

Regulatory Implications

The filing is a standard 10-Q report, adhering to SEC regulations for quarterly financial disclosures by public companies.

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements.
2. Analyze the terms of the Lincoln Park Capital Fund Purchase Agreement and Equity Line of Credit.
3. Investigate the company's historical name changes for potential insights into past financial strategies.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q.
• 2024-05-15: Filing Date — Date the 10-Q was officially filed with the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC), that provides a continuing disclosure by public companies. (Provides a snapshot of the company's financial performance and operations for the specified quarter.)

Year-Over-Year Comparison

This 10-Q filing covers the period ending March 31, 2024, providing updated financial information compared to previous filings.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AWH The Nasdaq Capital Ma

Filing Documents

• awh-20240331.htm (10-Q) — 1324KB
• awh-ex31_1.htm (EX-31.1) — 14KB
• awh-ex31_2.htm (EX-31.2) — 14KB
• awh-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-24-060401.txt (&nbsp;) — 6035KB
• awh-20240331.xsd (EX-101.SCH) — 973KB
• awh-20240331_htm.xml (XML) — 913KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 2 Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity for the three months ended March 31, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 5 Notes to Condensed Consolidated Financial Statements 6 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4

Controls and Procedures

Controls and Procedures 27 PART II Other Information 29 Item 1

Legal Proceedings

Legal Proceedings 29 Item 1A

Risk Factors

Risk Factors 29 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3 Defaults Upon Senior Securities 30 Item 4 Mine Safety Disclosures 30 Item 5 Other Information 30 Item 6 Exhibits 31

SIGNATURES

SIGNATURES 32 The following are registered and unregistered trademarks and service marks of Aspira Women's Health Inc.: VERMILLION SM , Aspira Women's Health , OVA1 , OVERA , ASPiRA LABS , OvaCalc , OVASUITE SM , ASPiRA GenetiX SM , OVA1PLUS , OVAWATCH , EndoCheck SM , OVAInherit SM , Aspira Synergy , , OVA360 SM , ASPIRA IVD SM , and YOUR HEALTH, OUR PASSION . i

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Aspira Women's Health Inc. Condensed Consolidated Balance Sheets (unaudited) (Amounts in Thousands, Except Share and Par Value Amounts) March 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 3,413 $ 2,597 Accounts receivable, net of reserves of $ 2 and $ 15 , as of March 31, 2024 and December 31, 2023, respectively 1,531 1,459 Prepaid expenses and other current assets 942 997 Inventories 236 227 Total current assets 6,122 5,280 Property and equipment, net 131 165 Right-of-use assets 620 528 Restricted cash 260 258 Other assets 31 31 Total assets $ 7,164 $ 6,262 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 1,643 $ 1,261 Accrued liabilities 2,797 2,863 Current portion of long-term debt 249 166 Short-term debt 416 670 Current maturities of lease liabilities 188 159 Total current liabilities 5,293 5,119 Non-current liabilities: Long-term debt 1,347 1,430 Non-current maturities of lease liabilities 487 427 Warrant liabilities 1,400 1,651 Total liabilities 8,527 8,627 Commitments and contingencies (Note 4) Stockholders' deficit: Common stock, par value $ 0.001 per share, 200,000,000 and 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 12,344,104 and 10,645,049 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 12 11 Additional paid-in capital 521,557 515,927 Accumulated deficit ( 522,932 ) ( 518,303 ) Total stockholders' deficit ( 1,363 ) ( 2,365 ) Total liabilities and stockholders' deficit $ 7,164 $ 6,262 See accompanying notes to the unaudited condensed consolidated financial statements. 1 Aspira Women's Health Inc. Condensed Consolidated Statements of Operations (unaudited) (Amounts in Thousands, Except

View Full Filing

View this 10-Q filing on SEC EDGAR